Relapse of severe sarcoidosis with an uncommon peritoneal location after TNFalpha blockade. Efficacy of rituximab, report of a single case.
Dasilva
Virginie
V
Breuil
Véronique
V
Chevallier
Patrick
P
Euller-Ziegler
Liana
L
D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D005260:Female; D005938:Glucocorticoids / Q000494:pharmacology; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000494:pharmacology; D000069285:Infliximab; D008727:Methotrexate / Q000494:pharmacology; D008875:Middle Aged; D010532:Peritoneal Diseases / Q000188:drug therapy / Q000209:etiology / Q000473:pathology*; D000069283:Rituximab; D012507:Sarcoidosis / Q000150:complications / Q000188:drug therapy / Q000473:pathology*; D055502:Secondary Prevention; D017211:Treatment Failure; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D005938:Glucocorticoids; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000069283:Rituximab; D000069285:Infliximab; D008727:Methotrexate